CrossrefInfokarte
Evaluation of the Lifetime Benefits of Metformin and SGLT2 Inhibitors in Type 2 Diabetes Mellitus Patients with Cardiovascular Disease: A Systematic Review and Two-Stage Meta-Analysis
American Journal of Cardiovascular Drugs · 2024-05 · 24 (3) · 371-383
DOI: 10.1007/s40256-024-00640-w ↗Abstract
Kein Abstract verfügbar.
EUVIMED